# Investigation of Sugammadex in Outpatient Urological Procedures

> **NCT03138967** · PHASE4 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 54 (actual)

## Conditions studied

- Malignant Neoplasms of Urinary Tract
- Bladder Cancer

## Interventions

- **DRUG:** Rocuronium
- **DRUG:** Sugammadex
- **DRUG:** Neostigmine
- **DRUG:** Glycopyrrolate

## Key facts

- **NCT ID:** NCT03138967
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2018-09-01
- **Final completion:** 2019-11-24
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2020-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03138967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03138967, "Investigation of Sugammadex in Outpatient Urological Procedures". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03138967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*